INTRODUCTION
Egypt has the highest number of hepatitis C virus (HCV) cases globally it is about14.7 % and over 90% of the infections have been reported to be HCV genotype 4 [4, 5] .
Until 2012, the combination of pegylated interferon-α (peg IFN) and ribavirin (RBV) was the standard of care (SOC) in chronic HCV with a sustained virological response (SVR) in approximately 40-50% of genotype 1 patients after 48 weeks of therapy and 70-80% for genotype 2 and 3 patients after 24 weeks of therapy [6] . Sofosbuvir is a nucleotide analogue NS5B polymerase inhibitor approved by the Food and Drug Administration on December 6, 2013, for the treatment of chronic HCV infection as a component of antiviral treatment regimen; it shows high antiviral activity against all HCV genotypes and a high barrier to resistance [7] . Sofosbuvir has an excellent tolerability and safety. Most severe adverse effects were observed when sofosbuvir was combined with ribavirin and/or pegylated interferon. In the clinical trials of sofosbuvir, the percentage of chronic HCV cases who stopped treatment due to adverse effects was 4% in placebo groups, 1% in sofosbuvir plus ribavirin groups and 2% in sofosbuvir plus pegylated interferon and ribavirin groups [8] .
This study aimed to compare double therapy (sofosbuvir + ribavirin) for 24 weeks and triple therapy (sofosbuvir + ribavirin +peg-INF) for 12 weeks for chronic HCV infection in Egyptian patients as regards efficacy and adverse effects.
PATIENTS AND METHODS
This study was conducted in Tropical Medicine Department, Zagazig University Hospitals in the period between August 2015 and April 2016. Seventy two patients were included.
Inclusion criteria:
Patients with chronic hepatitis C virus infection diagnosed with positive PCR, without cirrhosis or with compensated cirrhosis diagnosed by combination of clinical, laboratory and radiological parameters Follow up: Patients were followed up throughout treatment by clinical evaluation, CBC, liver function after 1 week of treatment then every month till end of treatment and PCR for HCV RNA after 4 weeks, End of Treatment (EOTR) and 3 months after stoppage of therapy for triple therapy group and after 4 weeks, 12 weeks, EOTR and 3 months after stoppage of therapy for double therapy group.  The primary efficacy end point was the percentage of patients in each group with SVR 12, defined as HCV RNA <15 IU/mL 12 weeks after stoppage of treatment.  Treatment was expected to be stopped for patients with the following criteria : HCV RNA ≥ the lower limit of quantification (LLOQ) after 2 consecutive HCV RNA < LLOQ, Confirmed HCV RNA >1 log 10 increase from nadir, HCV RNA ≥ LLOQ through 8 weeks of treatment, Severe bacterial infection or serious adverse events.  Patients in the two groups were followed up monthly during treatment and for 3 months after end of treatment for any developed adverse effects with complete analysis including onset, course, duration, association, frequency, if the patient asked for medical advice, took any medications and if had been admitted to hospital for these side effects.  Grading of these adverse effects was done according to the common terminology criteria of adverse events 2010 as follows: Table ( 1) shows that there was no significant difference between the two groups as regards demographic data. When we compared the baseline laboratory parameters of the two patients groups we found significant differences as regards platelets count, bilirubin, albumin and liver enzymes serum levels as shown in table (2),while there was no significant differences between the two groups in the hemoglobin concentration, WBC's count, PCR, percentage of cirrhotic patients or percentage of splenomegally. There was no significant difference between the two groups in the virological response all through the period of treatment as seen in table (3).
RESULTS
The comparing of the two groups as regards the expected side effects of treatment revealed that there was no significant difference between them, except for fatigue and flu-like symptoms which were encountered more frequently in group II as seen in table (4). Table 5 compares between the two groups as regards the value of the change in their laboratory levels from base time to end of treatment and revealed that the increase in bilirubin level was significantly higher in group II, while significant decline in the level of enzymes ALT and AST in group I when compared to group II. This work is aimed to compare the two regimens, double regimen (sofosbuvir + ribavirin) and triple regimen (sofosbuvir + ribavirin +peg-INF) for treatment of chronic HCV infection in Egyptian patients as regards adverse effects (laboratory and clinical adverse effects) and efficacy (SVR and enzymatic response).
In current study, a significant difference was present between the two groups as regards baseline platelet count and serum albumin levels which were higher in triple therapy group, while the liver enzymes and bilirubin were higher in double therapy group, this difference in baseline data is explained by that the patients were not randomly selected but each patient was allocated to certain treatment group according to the NCCVH criteria for INF eligibility.
As regards virological response in this study, both regimens resulted in rapid suppression of HCV-RNA by week 4 in all patients (100%) with HCV-RNA <15 IU/ml. At the end of treatment, 100% of patients received triple or dual therapy had a HCV-RNA <15 IU/ml. This agrees with the results of Doss et al. [17] who noticed that by week four of therapy with sofosbuvir and ribavirin, all patients had HCV RNA less than the lower limit of quantification (LLOQ), and all of them had maintained virological suppression while receiving therapy. Also, these results were near to the results of NEUTRINO study, which was a single-group study of sofosbuvir plus peg interferon-ribavirin and by week 4, the percentage of patients with rapid and substantial decreases in serum HCV RNA levels was 99% [18] while, Ruane et al. [19] found that the HCV RNA levels declined rapidly from 5.97 log10 IU/ml to1.74 log10 IU/ml after only one week from starting treatment with sofosbuvir and ribavirin, all those results confirm rapidity, potency and value of sofosbuvir addition to treatment regimens.
The primary efficacy end point is a sustained virological response, which is HCV RNA level below the lower limit of quantification, at 12 weeks after the end of treatment (SVR12 All patients had suffered from adverse effects during treatment and most adverse effects were of grade 1 severity according to the CTCAE grading. Adverse effects were mild without intervention or affection of Activities of Daily Living (ADL) [12] . The reported adverse effects included constitutional adverse effects as fever, chills, flu-like symptoms, bone pain and fatigue however, no serious adverse effects were detected or any patient had stopped the treatment, this can be explained in part by the relatively short treatment duration in relation to the previous 48 weeks and on other hand, the safety of sofosbuvir and the close follow up.
Significant difference was present between the two groups as regards fatigue and flu like symptoms which were higher in triple therapy group than double therapy group. These results agree with the study of Ruane et al. [19] in which the most common adverse events were headache, insomnia and fatigue with no patient stopped treatment due to an adverse event.
In the studied groups, a Hemoglobin level <10 g/dL occurred in 22% of patients which is mostly due to hemolysis, a well-known adverse effect of ribavirin combination treatment with onset of hemolysis is usually after 2 to 3 weeks of therapy and it is a dose dependent, this could explain the same incidence rate of hemoglobin decrease below 10gm/dl although different duration of treatment in the 2 groups. On the other hand, thrombocytopenia <50 x 10 3 /mm 3 and leucopenia <3 x 10 3 /mm 3 were not reported in our study.
Multiple laboratory abnormalities had been encountered during follow up. Both groups showed reduction in hemoglobin, platelet count, WBC's count at end of treatment (EOTR) but the value of this reduction was not significantly different in both groups. This means that the hematological changes were nearly the same in both groups. This disagrees with Christensen et al. [21] who reported that reduction in the hemoglobin level is expected with ribavirin and reductions in the neutrophil count are expected with peg interferon, so patients with triple therapy are more liable to hematological disturbances than patients with double therapy. This can be explained by that the short duration of therapy (3 months in triple therapy group) had a role in these results.
In our study, a comparison between the two groups as regards the value of the change in their laboratory levels from base time to end of treatment revealed a significant change in bilirubin level in group II in comparison to the group I, although, it is a very mild increase in front of minimal decrease in group I .On the other hand, a significant change (decrease) in the level of enzymes (ALT and AST) in group I when compared to group II. This is probably due to longer treatment duration in group I (6 months) allowing for improving and normalization of bilirubin and liver enzymes.
CONCLUSION
Interferon-free regimen of sofosbuvir and ribavirin for 24 weeks is as successful in treatment of Egyptian patients with chronic HCV as the interferon-based triple therapy in association with sofosbuvir and ribavirin for 12 weeks and with higher tolerability and less side effects.
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